Close menu




November 29th, 2023 | 06:30 CET

MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

  • Biotechnology
  • Pharma
Photo credits: pixabay.com

2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.

time to read: 4 minutes | Author: Armin Schulz
ISIN: MORPHOSYS AG O.N. | DE0006632003 , CARDIOL THERAPEUTICS | CA14161Y2006 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    MorphoSys - Hopeful drug with mixed results

    The development of the MorphoSys share price in recent years has been a disaster. An overly expensive takeover of Constellation caused problems for the former biotech flagship company. Since the beginning of the year, new euphoria has been generated by the prospect of approval for the drug Pelabresib, which was in clinical Phase III. Pelabresib is aimed at a rare form of blood cancer and, according to experts, has a potential of billions. But even before the trial results, the quarterly results brought a noticeable setback. The operating result showed a minus of EUR 51 million.

    Turnover of EUR 63.8 million also fell by 30% compared to the previous year. The hopeful candidate, Monjuvi, contributed approximately EUR 21.5 million, slightly less than the EUR 21.9 million from the previous year. Nevertheless, the forecasts for the product were confirmed. Operating costs were EUR 7 million above 2022 and amounted to EUR 15.1 million. Research and development costs were reduced from EUR 77.8 million to EUR 63.2 million. This is due to prematurely terminated research projects and a reduction in headcount. At the end of the third quarter, MorphoSys had cash and cash equivalents of EUR 642.2 million.

    On November 20, the study results of pelabresib in myelofibrosis were presented. The results were mixed. On the one hand, there was a significant improvement in the reduction of spleen volume. This means that the primary objective was achieved, but the results of the secondary objective were disappointing. Here, the comparator drug ruxolitinib performed significantly better, so a combination therapy appears to make more sense. More detailed data will be presented at the 65th Annual Meeting of the American Society for Hematology. This news has attracted short sellers. After falling to EUR 14.52, the share has recovered to EUR 18.40. This rebound could be a result of short sellers covering their positions through purchases.

    Cardiol Therapeutics - MAvERIC-Pilot Study speeds up

    Among our candidates, the stock of Cardiol Therapeutics has performed the best thus far. Cardiol Therapeutics is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company has a strong financial position, a broad intellectual property portfolio and a product called CardiolRx™ that is in two Phase II trials for the treatment of recurrent pericarditis and acute myocarditis. The Company is also advancing the development of CRD-38, a subcutaneously administered drug for the treatment of heart failure.

    On November 1, the Company announced that more than 50% of the enrollment target for the Phase II MAvERIC-Pilot Study evaluating the safety and efficacy of CardiolRx™ in patients with recurrent pericarditis has been reached. The study aims to assess the improvement in objective disease characteristics and the feasibility of discontinuing background therapy, including corticosteroids, while taking CardiolRx™. The results of the pilot study will contribute to understanding the treatment profile of CardiolRx™ and developing the design of a pivotal Phase III trial.

    On November 16, study results were published showing that in an experimental model of pericarditis, mesothelial-to-mesenchymal transition (MMT) is induced. Treatment with cannabidiol, the active ingredient in CardiolRx™, inhibits this process. This finding suggests a potential benefit in preventing complications associated with pericarditis. The relevant studies were submitted by international research partners for the 2023 Annual Congress of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases in Belgrade. The shares, currently trading at USD 0.8899 on the NASDAQ, formed an upward trend again for the first time. This will remain intact as long as the USD 0.72 mark is not broken on a closing price basis.

    Bayer - The tree is burning

    Bayer's shares have been weak all year, but on November 20, they took another dive. The Group had previously announced the discontinuation of the drug development of asundexian with the study name OCEANIC-AF. The drug was one of the greatest hopes in the Pharma division's pipeline and was intended to help patients with atrial fibrillation and stroke risk. In contrast, the OCEANIC-STROKE phase III clinical trial is still ongoing. The Leverkusen-based company also had to recall a batch of the cancer drug Vitrakvi due to microbacterial contamination.

    In an interview with the Financial Times, CEO Bill Anderson said that the Company had invested too little in the pharmaceutical sector in the past and that this had ultimately led to a thin product pipeline. However, he assumes that the course for the future has now been set. As if the bad news about the pharma division was not enough, there were also setbacks regarding glyphosate. While the approval in the EU has been extended by 10 years, a court in the USA awarded the three plaintiffs USD 61.1 million in damages and imposed USD 1.5 billion in punitive damages.

    Further pressure on the share was exerted by a Bloomberg report according to which the Group had various parties run through spin-off scenarios. The aim was to be prepared for the demands of larger investors at an early stage. However, a result has not yet been reached. The pressure is growing, and the share is falling daily. Analysts have also become more cautious, and the majority have downgraded Bayer to "Hold". Only UBS, Bernstein Research and DZ Bank see Bayer as a "Buy". The share is approaching the psychologically important EUR 30 mark and is currently trading at EUR 30.66.


    Only Cardiol Therapeutics, who is financially well positioned and can report positive study results, is currently doing really well. MorphoSys was unable to fulfill the high hopes for the next blockbuster with Pelabresib. Caution is advised here. Bayer's pharma division has been the guarantor of success so far. If the biggest hopeful from the development pipeline fails and the glyphosate lawsuits continue unabated, this creates uncertainty. Is the share worth 25% less because of these incidents? Probably not. Nevertheless, one should not catch a falling knife.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read

    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

    Read

    Commented by Fabian Lorenz on February 14th, 2024 | 07:00 CET

    Plug Power, Bayer, Defense Metals: Shares in panic mode

    • Mining
    • RareEarths
    • Hydrogen
    • Pharma

    Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.

    Read